Sept 22 (Reuters) - Novo Nordisk A/S NOVOb.CO :
* SWITCHING TO INVESTIGATIONAL ONCE-WEEKLY INSULIN ICODEC FROM OTHER BASAL INSULINS DEMONSTRATED TO BE EFFICACIOUS AND WELL-TOLERATED FOR PEOPLE WITH TYPE 2 DIABETES IN PHASE 2 TRIAL
* NOVO NORDISK - ANNOUNCED RESULTS FROM THREE PHASE 2 CLINICAL TRIALS FOR INSULIN ICODEC
* NOVO NORDISK - PRIMARY ENDPOINT OF TRIAL SHOWED INSULIN ICODEC WITH LOADING DOSE SHOWED SIGNIFICANTLY GREATER 'TIME IN RANGE' VERSUS INSULIN GLARGINE U100